JOHN R. GUNN JOINS BERKELEY LIGHTS’ BOARD OF DIRECTORS

JOHN R. GUNN, FORMER CHIEF OPERATING OFFICER OF MEMORIAL SLOAN KETTERING CANCER CENTER, JOINS BERKELEY LIGHTS’ BOARD OF DIRECTORS

Emeryville, California– Tuesday–Aug 2, 2016 – Berkeley Lights, Inc. (BLI) today announced the appointment of John R. Gunn, former Chief Operating Officer for Memorial Sloan Kettering Cancer Center, to the Berkeley Lights’ board of directors.

“We are very pleased to have someone of John’s caliber and professional experience join the Board,” said Michael Marks, Chairman of the Berkeley Lights Board of Directors. “John’s breadth of knowledge in the introduction and use of advanced technologies in healthcare will be a valuable resource as we deliver our first commercial products later this year. His addition brings industry experience and guidance to our vision of enabling the development of point of care autologous cellular therapies.”

From 1987 to 2015, Mr. Gunn served as the chief operating officer of Memorial Sloan-Kettering Cancer Center, a cancer research and treatment center in New York. Mr. Gunn also serves on the boards of The Visiting Nurse Association of New York and the Greater New York Hospital Association.

“I am excited to join the Berkeley Lights Board because the company’s ground-breaking technology has the potential to transform immunology,” said Mr. Gunn. “Berkeley Lights’ systems can empower researchers and clinicians with a level of cellular specificity and accuracy that has the potential to significantly accelerate the speed that diseases are understood and therapies are discovered, tested and, eventually, are delivered.”

About Berkeley Lights

Founded in 2011 and headquartered in Emeryville, CA, Berkeley Lights, Inc. has developed technology, platforms and devices* that enable opto-nanofluidic biomedical engineering with the highest level of integration. Named a strategic partner with the Parker Institute for Cancer Immunology in April 2016, Berkeley Lights’ core belief is that biomedical challenges yield to world-class engineering. The company is applying its capabilities to address unmet research needs in BioPharma, Cellular Immuno-Oncology, and Autologous T-cell Therapies. For more information, visit http://berkeleylights.wpengine.com/ and follow @Berkeley_Lights on Twitter or on our LinkedIn page.

* For Research Use Only. Not for use in diagnostic procedures.

Media Contact:

Sandra Finley
Berkeley Lights, Inc.
407-386-6864